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Abstract: Olive leaf extract (OLE) has been used for many years for its putative health benefits, but,
to date, scientific evidence for the basis of these effects has been weak. Although recent literature
has described a link between ailments such as cardiovascular disease, diabetes and cancer and a
protective effect of polyphenols in the OLE, the mode of action is still unclear. Here, we describe
a double-blinded placebo (PBO)-controlled trial, in which gene expression profiles of peripheral
blood mononuclear cells from healthy male volunteers (n = 29) were analysed to identify genes that
responded to OLE, following an eight-week intervention with 20 mL daily consumption of either OLE
or PBO. Differences between groups were determined using an adjusted linear model. Subsequent
analyses indicated downregulation of genes important in inflammatory pathways, lipid metabolism
and cancer as a result of OLE consumption. Gene expression was verified by real-time PCR for
three genes (EGR1, COX-2 and ID3). The results presented here suggest that OLE consumption may
result in health benefits through influencing the expression of genes in inflammatory and metabolic
pathways. Future studies with a larger study group, including male and female participants, looking
into direct effects of OLE on lipid metabolism and inflammation are warranted.
Keywords: polyphenols; transcriptomics; nutraceutical; inflammation
1. Introduction
Although olive leaf extract (OLE) has been used for many years for its putative health benefits, the
mode of action by which these benefits occur is still unclear. In vitro and animal studies suggest that the
health benefits of OLE are due, at least in part, to OLE polyphenols influencing gene expression [1,2].
In vitro studies using human cell lines have suggested that OLE has anti-inflammatory [3] and
anti-cancer effects [2]. In vivo animal studies suggest that OLE attenuates obesity from a high fat
diet [4] and reduces impacts resulting from inflammatory cytokine production and insulin resistance [5].
These studies showed altered expression of genes in relevant pathways. Animal [6] and in vitro [7]
models have pointed towards interactions with Nrf2 (Nuclear factor erythroid 2-related factor 2)
signalling cascades as one effector for the health benefits of polyphenols. However, this hypothesis has
not been substantiated in human trials [8].
Int. J. Mol. Sci. 2016, 17, 2019; doi:10.3390/ijms17122019 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 2019 2 of 21
Recent research has shown improved blood pressure in hypertensive males with OLE [9] and
improved insulin sensitivity in overweight males [10]. These studies have focused on specific outcomes
or biomarkers such as improved insulin sensitivity or the expression of specific cytokines; however, a
more comprehensive analysis of the changes in gene expression has not been undertaken.
Investigating changes in gene expression profile after OLE consumption in humans will enable a
better understanding of the pathways involved. The genetic pathways and relationships uncovered
can be used to hypothesise the modes of action. This may help substantiate existing health benefits
and lead to the discovery of novel health benefits that may arise from the consumption of OLE.
This intervention study was focussed on identifying the genes and associated pathways that
respond to OLE treatment and to determine the underlying mechanisms that correlate to reported
health benefits. The tested product is designed for chronic consumption as a nutraceutical to improve
health in the long term, as opposed to medicines that are developed for short-term use to create
maximum results. A modest change over a long time is likely to manipulate health significantly [11].
Because the participants were healthy men, inflammatory and disease markers were in the healthy
range; therefore, reducing these is difficult to achieve. The results are therefore intended to be indicative
and to reveal important directions for future research.
2. Results
2.1. Participant Characteristics and Compliance, and Supplement Tolerance
A total of 32 men gave written consent and were enrolled in the study. Two participants were lost
to follow-up and one participant withdrew due to an adverse reaction to the supplement. The first
participants began the intervention on the 3 May 2015 and the last participants began on the 22 June
2015. The intervention ran for eight weeks.
Characteristics of the final 29 men (15 in the OLE arm and 14 in the placebo (PBO) arm of the
intervention) are shown in Appendix Table A1. There were no statistically significant differences
between intervention arms, or between the beginning and end of the intervention, for any of the
measured characteristics.
On average, participants taking the OLE did not achieve the instructed 20 mL per day, most likely
due to its bitter taste. However, the amount they did consume (~17 mL) means that their daily phenolic
intake was higher than that approved by European Food Safety Authority (EFSA), which is no less
than 5 mg of hydroxytyrosol (HT) per 20 mL of olive oil (OO) to provide protection of blood lipids
from oxidative stress. Furthermore, the polyphenol intake in the OLE group was clearly higher than
that of the PBO, who consumed slightly more than the instructed 20 mL.
No participants taking the PBO reported any adverse reactions and the OLE supplement was
well tolerated in most participants, with the exception of one participant, who reported nausea and
dropped out of the study after three days. Volunteers consistently reported that the OLE supplement
had an unpleasant, bitter taste and they did not enjoy taking it.
The three-day food diaries confirmed that participant diets did not contain abnormal amounts of
either polyphenol-rich foods or fish that could influence or bias the results. No changes in the food
intake between groups or time points were detected.
2.2. RNA Quality Control
The measured RNA Integrity Number (RIN) for all samples was above 8.0, demonstrating that
the RNA integrity was satisfactory for analysis. The RNA quality was evaluated again within the
computer programme Affymetrix Expression Console Software (version 1.4.1, Affymetrix, Santa Clara,
CA, USA) [12]. All bacterial control probes were measured in the correct order with increasing intensity,
indicating that both labelling and hybridising for the arrays were accurate. A signal boxplot confirmed
that the data were normally distributed.
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2.3. PBMC Transcription Profiles
Using the Benjamin and Hochberg method of False Discovery Rate (FDR) control [13] and
an adjusted p-value of <0.05, no genes would be considered significantly affected by the OLE
supplementation in comparison to PBO when assessed using microarrays. However, using the
less conservative statistical criterion of an unadjusted p-value <0.05, 2683 probes were differentially
expressed. In addition, 1576 were upregulated and 1107 were downregulated. A less conservative
p-value has been employed in similar human intervention studies [14,15].
Using a 1.4-fold change (FC) cut-off for expression, 27 genes were shown to be differentially
expressed; these genes were used for pathway analysis. This FC cut-off has been used in previous
nutrigenomic studies [14,16]. The genes were identified and classified using Gene Ontology (GO) [17,18]
and listed with gene names, FC, and p-values.
Genes with the highest FC had large confidence intervals, emphasizing high inter-individual
variance in gene expression. Genes such as G0/G1 switch 2 (G0S2) and chemokine (C-X-C motif ) ligand 8
(CXCL8, subsequently referred to as IL-8) showed large confidence intervals compared to EGR1,
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) ((PTGS2) referred
to as COX-2) and heparin-binding EGF-like growth factor (HBEGF) (Table 1). Changes in participant
gene expression tended to show downregulation opposed to upregulation after OLE supplementation
compared to PBO.
Table 1. Fold change (FC) in gene expression after olive leaf extract (OLE) supplementation relative to
placebo (PBO) with p-values.
Gene Symbol Gene Name FC p-Value
G0S2 G0/G1 switch 2 −3.121 9.65 × 10−3
EGR1 early growth response 1 −2.54 1.81 × 10−2
CXCL8 (IL-8) chemokine (C-X-C motif) ligand 8 −2.397 3.93 × 10−2
COX-2 (PTGS2) prostaglandin-endoperoxide synthase 2 −2.241 7.49 × 10−3
EGR2 early growth response 2 −1.978 2.77 × 10−2
KLF3 Kruppel-like factor 3 (basic) −1.858 1.08 × 10−2
HBEGF heparin-binding EGF (epidermal growth factor)-like growth factor −1.786 1.30 × 10−4
NR4A2 nuclear receptor subfamily 4, group A, member 2 −1.625 3.29 × 10−2
NDC80 NDC80 kinetochore complex component −1.599 3.48 × 10−4
MXD1 MAX (myc-associated factor X) dimerization protein 1 −1.543 3.36 × 10−2
NCAPG non-SMC (Structural Maintenance of Chromosomes)condensin I complex, subunit G −1.526 2.67 × 10
−2
OSM oncostatin M −1.428 2.98 × 10−2
NAP1L3 nucleosome assembly protein 1-like 3 1.463 8.88 × 10−3
MIER3 mesoderm induction early response 1, family member 3 1.47 6.14 × 10−4
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1.483 9.27× 10−3
2.4. Gene Ontology: Gene Annotation Tool to Help Explain Relationships (GATHER) and Protein Analysis
through Evolutionary Relationships (PANTHER)
Several physiological and biological processes were identified by GATHER [19] when genes with
an FC > 1.4 were analysed GO indicated that OLE was having several effects on gene expression
(Appendix Table A4). However, the identified pathways achieved low Bayes factors and encompassed
a wide range of functions potentially regulated; therefore, further analysis was required.
Genes with FC > 1.4 were entered into the online tool, PANTHER [20], for functional classification.
The top pathway identified was cholecystokinin receptor (CCKR). Pathways related to inflammation
were also highlighted, with chemokine and cytokine signalling and interleukin signalling appearing
in the top altered pathways (Figure 1a). The biological processes identified by Panther confirmed
a change associated with immune function; however, metabolic processes and apoptosis were the
strongest relationships identified (Figure 1b).
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Figure 1. Gene classification pie charts created in PANTHER (Protein ANalysis THrough 
Evolutionary Relationships). (a) pathways; and (b) biological process associated with the >1.4-fold 
change (FC) gene expression change in response to olive leaf extract (OLE) consumption. The key 
names the pathways (starting from the top and moving clockwise) that have been regulated with OLE 
relative to placebo (PBO)  
2.5. Ingenuity Pathway Analysis (IPA) 
To identify the biological processes altered by OLE supplementation, the genes with significant 
changes in expression were entered into the bioinformatics program Ingenuity Pathway Analysis, 
build version 346717M (QIAGEN, Redwood City, CA, USA) [21]. Using genes at an FC of >1.4 and  
a p-value of <0.05 indicated an anti-inflammatory effect with the top canonical pathways associated 
with cancer, inflammatory disease, and arthritis.  
Using an FC > 1.4, the cumulative effects of small changes in gene expression are likely to have 
been overlooked. A further analysis was therefore undertaken including all genes that were 
significantly altered (p < 0.05. A FC of >1.4 predominantly identified genes involved downstream or 
at the end of pathways for inflammation. Significantly (p < 0.05) altered genes with a lower FC may 
play a pivotal role in these downstream changes. For example, the amplification of kinase cascades 
means that molecules upstream are likely to have a much lower FC than downstream molecules, 
Figure 1. Gene classification pie charts created in PANTHER (Protein ANalysis THrough Evolutionary
Relationships). (a) pathways; and (b) biological process associated with the >1.4-fold change (FC)
gene expression change in response to olive leaf extract (OLE) consumption. The key names the
pathways (starting from the top and moving clockwise) that have been regulated with OLE relative to
placebo (PBO).
2.5. Ingenuity Pathway Analysis (IPA)
To identify the biological processes altered by OLE supplementation, the genes with significant
changes in expression were entered into the bioinformatics program Ingenuity Pathway Analysis,
build version 346717M (QIAGEN, Redwood City, CA, USA) [21]. Using genes at an FC of >1.4 and
a p-value of <0.05 indicated an anti-inflammatory effect with the top canonical pathways associated
with cancer, inflammatory disease, and arthritis.
Using an FC > 1.4, the cumulative effects of small changes in gene expression are likely to
have been overlooked. A further analysis was therefore undertaken including all genes that were
significantly altered (p < 0.05. A FC of >1.4 predominantly identified genes involved downstream or
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at the end of pathways for inflammation. Significantly (p < 0.05) altered genes with a lower FC may
play a pivotal role in these downstream changes. For example, the amplification of kinase cascades
means that molecules upstream are likely to have a much lower FC than downstream molecules, while
still exerting an important biological effect. The analysis regardless of FC identified Phospholipase
(PLA; p = 1.89 × 10−3) and Cholesterol Biosynthesis (p = 2.89 × 10−3) as the top pathways (Figure 2).
The top diseases and disorders identified were Cancer and Organismal Injury and Abnormalities,
corresponding with the results obtained using the 1.4 FC cut-off.
Phospholipases are a key component of inflammation via their release of arachidonic acid (AA),
which interacts with COX-2 to produce prostaglandins (Figure 3). At >1.4 FC, Prostanoid Biosynthesis
was highlighted as a key pathway; this is regulated by COX enzymes and produces an inflammatory
response when activated. Metabolism of membrane lipid derivatives and cholesterol concentration
interconnect and relate to the PLA pathway.
The majority of the pathways altered were downregulated (negative z-score) or had genes
changed in both directions (no activity pattern predicted), although the effect of a gene being up or
downregulated depends on its function within the pathway. The “Antioxidant Action of Vitamin
C” pathway was upregulated (positive z-score) (Figure 2). If OLE was acting as an antioxidant, this
pathway would be predicted to act in a similar way to vitamin C.
Another pathway with a predicted downregulation was the Wnt/β-catenin canonical pathway
(p = 3.7 × 10−3) (Figure 2). This plays an important role in cancer progression, adipogenesis, and lipolysis.
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Figure 2. Canonical pathways affected after OLE supplementation under the criteria p < 0.05.  
A positive z-score (orange) indicates that gene expression is upregulated, while a negative score 
(blue) represents downregulated expression. The grey bars contain genes that are up and 
downregulated; therefore, the activity pattern cannot be determined. Ratio is the number of genes 
from a pathway that were altered with OLE consumption. The p-value for each pathway is presented 
on a log scale to allow easier visualisation. 
i re 2. a ical at a s affecte after s le e tati er t e criteria p 0.05.
A positive z-score (orange) indicates that gene expression is upregulated, while a negative
score (blue) represents downregulated expression. The grey bars contain genes that are up and
downregulated; therefore, the activity pattern cannot be determined. Ratio is the number of genes
from a pathway that were altered with OLE consumption. The p-value for each pathway is presented
on a log scale to allow easier visualisation.
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Figure 3. Macrophage migration inhibitory factor ( IF) regulation of innate i munity canonical
pathway. Cytokine production is circled in green because there are several related cytokines, including
IL-8 (−2.4 FC) and oncostatin M (OSM) (−1.43 FC), which were downregulated with OLE consumption.
JNK has been circled because of its relevance to JUNB regulation (downregulated in this study
with −1.3 FC), which has recently been revealed to play a similar role in activating AP1 and
inflammation [22].
2.5.1. Upstream Regulators
Using the measured changes in gene expression, IPA can be used to elucidate the biological causes
and the downstream effects on cellular and organismal biology. This analysis showed that ERK1/2
(extracellular signal–regulated kinases1/2) inhibition, via NF-κB downregulation, could result in the
observed expression of several inflammatory and cancer related genes (Figure 4).
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Pathways Analysis Network in IPA predicted how changes in the ERK1/2 pathway could result
in the observed changes in gene expression due to OLE consumption.
2.5.2. Real-Time PCR Confirmation of Array Expression
The expression levels of three genes (EGR1, COX-2 and ID3) were evaluated with real-time
PCR to validate the microarray results. An upregulated gene (EGR1) and a downregulated (ID3)
were chosen to validate if the Affymetrix array had measured up and downregulated genes correctly.
The expression of COX-2 was also compared because this gene had interesting implications for
inflammation. Gene expression was normalised against the housekeeping genes GAPDH and ACTB
(β-actin); both of these showed consistent expression across participants, indicating that they are
appropriate to use as housekeeping genes. The results measured by real-time PCR for EGR1, COX-2,
and ID3 were consistent with the microarray data (Table 2).
Table 2. Real-time PCR confirmation of the gene expression measured by Affymetrix arrays. Differential
expression of EGR1, COX-2 and ID3 following the eight-week supplementation with OLE relative




Real-time PCR −2.18052 −1.73258 1.801411
Standard deviation 0.141586 0.145314 0.10132
Affymetrix Array −2.54 −2.24 1.48
p-Value 1.81 × 10−2 7.49 × 10−3 9.27 × 10−3
3. Discussion
To our knowledge, this is the first study that has used transcriptomics methods to analyse the gene
expression changes associated with OLE consumption in humans. It is important to acknowledge that
this was a preliminary study to identify where changes in gene expression are occurring. The sample
size was small. Thus, the results are indicative rather than conclusive but will help guide the direction
of future research. The results suggest that anti-inflammatory and cancer-related gene expression
changes are associated with the consumption of OLE and could explain the health benefits claimed
with traditional use. Changes in gene expression indicate that the anti-inflammatory profile involves
phospholipase and inflammatory pathways. There was very little evidence that changes in gene
expression relating to the phase II enzymes and the Nrf2 canonical pathway were altered by OLE
consumption, although inhibition of this pathway by olive oil phenolics has been suggested as
instrumental in oxidative and inflammatory protection [6,7]. Many of the downregulated genes are
pivotal in inflammation and disease (OSM, COX-2 and IL-8). Metabolic processes were also emphasized
and an important lipolysis-related gene (G0S2) was altered by OLE consumption.
3.1. Gene Expression in PBMCs
PBMCs were chosen for analysis because they are easily accessible and express many genes
believed to be restricted to non-blood tissues that respond to micro and macro alterations to organs,
and will reflect effects of diet and nutrients [23,24]. Although mRNA expression profiles do not allow
direct determination of protein function (especially those involved in phosphorylation signalling
cascades), they do allow investigation of novel signalling pathways that OLE polyphenols may act
through in human PBMCs. In a sample of healthy people taking a nutraceutical, changes are likely
to be numerous but subtle [25], and thus it was not unexpected that the FC and significance of gene
expression was not very strong. It is acknowledged that in this study, using an adjusted p-value
cut off at 0.05, no changes in gene expressions would be deemed statistically significant. Therefore,
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an unadjusted p-value cut off at 0.05 was used. Three genes differentially expressed in response
to supplementation were selected for validation with real-time PCR. One gene was significantly
downregulated (EGR1) and one gene was significantly upregulated (ID3) when assessed by microarray.
The third gene (COX-2) was selected because it plays an important role in inflammatory and cancer
pathways. The expression levels between microarrays and real-time PCR for all three genes were
similar, giving credibility to the use of unadjusted p-values for microarray analysis. All three genes
used for validation play a role in cancer.
Many of the top genes downregulated in response to OLE were relevant to chronic and acute
inflammation. Pathway analysis correlated the expression to inflammation and metabolic processes
and identified cancer, arthritis, and adipogenesis as relevant. A recent study identified potential target
genes for therapy for inflammation (COX-2), immune imbalance (IL-8), and active atherosclerosis
(OSM) [26]. These genes were all downregulated with OLE.
3.2. COX-2 Expression in PBMCs
Research around the inflammatory enzyme COX-2 is extensive. This gene encoding this enzyme
(COX-2) was downregulated in response to OLE consumption. At the time this study was completed,
there were no existing studies that had demonstrated that olive polyphenols were able to regulate
COX-2 beyond post-prandial consumption in healthy humans.
Interest in the anti-inflammatory properties of oleocanthal (an olive phenolic) was motivated by a
study that demonstrated its ability to decrease the COX-2 enzyme levels in vitro [27]. Expression of
the gene was not investigated. It was hypothesized that oleocanthal was acting in a similar manner
to ibuprofen (IB) (inhibiting the enzyme) but to gain the same effects that the recommended dose of
IB has on COX-2, it has been estimated that approximately 500 g of extra virgin OO (EVOO) would
need to be consumed each day [27]. This is clearly not a realistic daily dose. COX-2 inhibition has
been definitively demonstrated in cell models [28,29] and mice [30,31] treated with olive polyphenols.
Cell models used polyphenol extract while the animal models have distributed it in their food with
OO or refined oil, respectively.
3.3. IL-8 Expression in PBMCs
In this study, IL-8 was downregulated with OLE. This corresponds to the most recent in vivo
work with the same OLE supplement in humans in which reduced levels of IL-8 were observed in
blood taken from participants after a six-week intervention [9]. Ex vivo work by this group has also
shown that OLE is able to downregulate IL-8 [32]. Another study looking at overweight males found
no changes to IL-8 with OLE IL-8 is a pro-inflammatory chemokine involved in cellular response
to inflammation, tumour proliferation, and has been acknowledged to play an important role in
cancer [33]. IL-8 is a target gene of NF-κB [34], and, as mentioned above, has been identified as a
potential target therapy for immune imbalance.
3.4. Other Genes with Inflammatory Relevance
This study measured a downregulation of transcription factor jun-B (JUNB) with OLE. JUNB is
an AP1 transcription factor correlated to immune function, and recent experimental work has
demonstrated its pivotal role in macrophage activation [22,35]. JUNB can be directly activated by
NF-κB in dendritic cells with LPS stimulation [36] and is required for the full activation of IL1β and
tumor necrosis factor (TNF) in macrophages stimulated by LPS [22].
Heparin binding EGF-like growth factor (HBEGF) was also downregulated with OLE. This growth
factor is activated by the transcription factors AP1 and NF-κB and plays a role in cancer and other
chronic diseases [37]. Upregulation of HBEGF has been observed in several cancer cells including breast
(MDA-MB-231) and prostate (PC3), and it has been suggested as a potential target for treatment [38].
Its upregulation has also been correlated to NF-κB activation of inflammatory cytokines [39].
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OSM was downregulated with OLE consumption in this study. This gene encodes the
pro-inflammatory cytokine OSM, expression of which has been correlated with metastasis of cancer
tumours [40,41]. In endometrial cancer, OSM was shown to activate STAT3, enhance cell migration and
invasion in vitro and promote cell proliferation, growth and angiogenesis in vivo [42]. OSM receptor
knock-out (KO) mice with cardiac disease have demonstrated improved survival and cardiac
performance [43]; therefore, OSM could be a target for protection from cardiovascular complications.
3.5. NF-κB Inflammatory Pathway
The transcription factor NF-κB activates >150 genes in response to stress [44]. The NF-κB
complex resides inactively within the cytoplasm due to the presence of the inhibitor molecule IκB [45].
Measuring changes in the gene expression of NF-κB is largely ineffective because it is already present
and therefore does not require further protein synthesis, merely activation. The kinases inhibitor of
nuclear factor κB kinase subunit (IKK)α and IKKβ phosphorylate IκB proteins, allowing NF-κB to
enter the nucleus, bind to promoter regions of target genes and enhance transcription of genes [46].
The intervention work revealed no measurable change in expression of IκB or NF-κB, although there
was a modest decrease in the expression of IKKβ. This would result in decreased phosphorylation of
IκB and therefore decreased release of NF-κB. IKK can be triggered by pro-inflammatory cytokines [47].
MyD88 was also downregulated and plays an important role in the activation of NF-κB triggered
by TLRs. Lastly, NKAPL was downregulated with OLE. An in vivo model has demonstrated that its
suppression leads to downregulation of NF-κB via inhibiting TNF and IL1β [48].
MAPK/AP1 may also play a role in OLE inflammatory changes. In this study, JUNB expression
was downregulated, and this plays a role in the MAPK pathway (Figure 3).
3.6. Lipid Metabolism and Anti-Inflammatory Gene Expression
The top canonical pathway identified by pathway analysis was PLA. Phospholipases are
enzymes that hydrolyse phospholipids into fatty acids and are categorized by the type of reaction
they catalyse [49]. The genes involved in changes with OLE were predominantly associated with
phospholipase A2 (PLA2) and then from within Phospholipase C (PLC). The PLC enzymes play an
important role in cell signalling, proliferation and differentiation [50].
PLA2 plays an important role in inflammation via the release of arachidonic acid (AA) from
the phospholipid membrane [51]. AA is transformed into prostaglandin (PGE2), which is converted
by COXs to eicosanoids (including prostaglandins and leukotrienes), which influence both innate
and adaptive immunity [52,53]. The downregulation of COX-2 observed in this study could restrict
prostanoid (prostaglandin, thromboxane and prostacyclin) production from AA. Many diseases and
their related complications have been correlated to PLA2 upregulation, including cardiovascular
complications, atherosclerosis, vascular inflammation, cancer and obesity [53–56]. Inhibition of this
pathway would partially explain the downregulation of inflammatory genes in this study.
G0S2 showed the strongest FC in expression after OLE consumption compared to all the other
regulated genes, which is a novel finding. This gene has recently been highlighted for its ability
to inhibit adipose triglyceride lipase (ATGL) which is key for the mobilization of triacylglycerol
stores [57]. We are not aware of any studies that have reported or investigated changes in G0S2 with
polyphenols. G0S2 KO in high fat diet-fed mice protects from obesity and insulin resistance, and
increases thermogenesis [58–60]. Zhang et al. [59] measured an increase in ketogenesis (measured by
plasma ketones). Silencing of G0S2 prevented adipocytes from differentiation, while overexpression
activated progression from pre-adipocytes to mature adipocytes in vitro and in vivo. G0S2 KO reduced
fat mass, lipid droplet size and the adipogenesis pathway in mice [57]. This suggests that G0S2 is a key
regulator of energy homeostasis, mediating lipolysis and fatty acid oxidation, and a downregulation
of this gene could be beneficial in the treatment of both obesity and obesity-related diseases.
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3.7. Gene Expression Change and Health Outcomes
The anti-inflammatory gene expression demonstrates that changes are not merely due to
anti-oxidising capacity as was historically hypothesised. Downregulating the AA and NF-κB pathways
could explain many of the health benefits attributed to OLE with traditional use. These include pain,
inflammatory related diseases such as cancer, diabetes, cardiovascular disease, and an improved acute
immune response.
Chronic inflammation is linked to many diseases including cancer and cardiovascular disease.
COX-2 is a strong driver of inflammation, and, therefore, has been an important area of focus [61].
The AA pathway and PGE2 production have been correlated with cancer and are also known
as the “inflammogenesis of cancer” [53]. Regular intake of COX-2 inhibitors such as aspirin has
been associated with a reduced risk of death due to cancers including prostate and breast [61–63].
Upregulation of COX-2 is found in skin, breast, prostate, bladder and pancreatic carcinomas [64].
Inhibiting COX-2 and thereby reducing prostaglandins could also explain improvements in Blood
Pressure (BP) measured in humans after OLE consumption [9]. HT administered to rats was able to
reduce thromboxane B2 and platelet aggregation in blood [65]. In a model using hypertensive rats,
COX-2 inhibitors reduced Prostaglandin F2α (PGF2α) expression, improved endothelial relaxation and
reduced BP [66]. In humans, intake of high phenolic enriched OO has also shown improved BP with
reduced chemokine (C-X-C motif) receptor 2 (IL8RA) and other genes related to BP [67]. This study
explained that the reduction in IL8RA could influence the renin–angiotensin–aldosterone system II,
which plays an important role in blood pressure and thereby hypertension. Although IL8RA was
not identified in our study, it is a specific receptor for IL-8. In studies investigating postprandial
effects of olive oil phenolic consumption in humans, the anti-inflammatory profile was evident but an
upregulation in cholesterol efflux was also demonstrated [68,69]. Cholesterol accumulation in immune
cells leads to inflammatory responses, which, in turn, can lead to decreased cholesterol efflux and
further inflammation [70]. A reduction in oxidised cholesterol could help explain the anti-inflammatory
profile measured with OLE in our study.
In downregulating acute inflammation, OLE would be hypothesized to compromise the immune
system and conceivably facilitate infection. More recently, it has been suggested that bacteria may
benefit from and further stimulate PGE2 synthesis in order to compromise the gut and lung linings of
the host [71]. In human macrophages, an inhibition of COX-2 reduced H5N1 infected pro-inflammatory
response and virus replication, the work indicated the virus required COX-2 pathway activation in
order to replicate [72]. IL-8 production is also activated by influenza [73]. A downregulation of
inflammatory related genes as observed in this study with OLE could improve immune function and
defence against pathogen attack.
This study demonstrated downregulation in G0S2 with OLE supplementation. If G0S2 was able to
downregulate free fatty acid (FFA) or adipogenesis, this could contribute to the reduced inflammatory
profile measured in participants taking OLE in this study.
4. Materials and Methods
4.1. Study Design
The study was a parallel double-blind randomised controlled trial conducted according to the
ethical guidelines laid down by the Declaration of Helsinki 1975, and approved by the New Zealand
Health and Disability Ethics Committees (15/NTB/27). The study was registered with the Australian
New Zealand Clinical Trials Registry (ACTRN12615001021561). An 8-week intervention time was
based on a previous 6-week intervention study measuring changes in BP after supplementation with
the same OLE product [9]. A more recent study looking at polyphenols in the diet using a parallel
design also used 8 weeks to successfully detect changes in inflammation [74]. OLE and Mediterranean
Diet benefits to health are correlated to long-term exposure; therefore, this study was looking for an
alteration in gene expression that was not merely a post-prandial effect. Thirty-three male subjects were
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given either a liquid OLE supplement or PBO (Appendix Table A2). Exclusion criteria included the
consumption of anti-inflammatories (such as low dose aspirin), antioxidant supplements, cholesterol
or blood pressure medicine, and antibiotics in the past month (Appendix Figure A1). Participants were
instructed to take 10 mL of their supplement twice a day with meals for 8 weeks. Measuring spoons
were provided. Participants attended a clinical visit at the beginning of the trial where they gave a
fasted blood sample and completed their initial Food diary. After the 8-week intervention, participants
returned for their second visit where they gave a fasted blood sample. A second food diary was
handed in at this appointment. An 8–10 mL blood sample was collected in ethylenediaminetetraacetic
acid (EDTA) tubes at the Faculty of Medical and Health Sciences, Grafton campus, The University of
Auckland by a registered nurse.
4.2. Test Product
“Olive Leaf Extract Extra Strength” is a commercially available OLE liquid concentrate
manufactured and bottled by Comvita New Zealand Limited (Paengaroa, Te Puke, New Zealand)
(Appendix Table A2). Both OLE and PBO were analysed by high performance liquid chromatography
(HPLC), which allowed the type and concentrations of polyphenols to be determined. This showed
that the PBO contained no polyphenols (Appendix Table A3). A 10 mL dose twice a day provided
121.8 mg of Oleuropein and 6.4 mg of HT daily. Tests have shown that even at high concentrations,
OLE is not genotoxic [75].
4.3. Statistical Analysis and Sample Size
There was no published literature on OLE and transcriptomic outcomes in humans at the time
this research was undertaken; therefore, OO phenolic studies in humans were utilized to inform
statistical decisions.
Standard deviation and differential expression of the JUN gene in healthy volunteers was taken
from a previous study looking at changes with OO phenolics [76]. This standard deviation was used
to calculate a total sample of 32 participants allowing >80% power to detect a significant difference in
JUN gene expression between intervention groups assuming a dropout rate of 10% and a 2-sided type
error of 0.05. The linear models for microarray analysis (Limma) model [77] was used for analysing
gene expression pre and post intervention, paired by participant.
4.4. Dietary Assessment
All volunteers were asked to complete a diet and activity profile, using the University of Auckland
standard 3-day food and activity diary.
The food intake diaries collected pre and post-supplementation were analysed using Foodworks
Professional 2012 (Xyris Software (Australia) Pty Ltd., Brisbane, Autralia) and the New Zealand food
composition tables. These were used to estimate changes that could impact the gene expression
measured in PBMCs, such as high alcohol or polyphenol consumption over the days before the clinical
visit. The diary was also used to measure any changes in the diet that may have occurred after taking
the supplement.
4.5. Compliance
Volunteers from both intervention arms were contacted fortnightly by the coordinating
investigator to confirm that the supplement was being taken and there were no problems.
The instructions were to take 20 mL per day of the cardiovascular strength OLE, delivering 121.8 mg
of oleuropein and 6.4 mg HT. Remaining supplement was returned at the end of the study, and this
was used to estimate the amount of supplement taken.
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4.6. Gene Expression Arrays
PBMCs were extracted from the blood samples by Ficoll–Paque density gradient centrifugation
(Ficoll–PaqueTM Premium, Global Science and Technology, Auckland, New Zealand) and stored until
RNA extraction.
All RNA samples were extracted from PBMCs in batches using the RNeasy Plus Mini Kit
(QIAGEN, Victoria, Australia) following the manufacturer’s recommended protocol.
RNA was quantified using the NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE, USA) and quality tested using the Bioanalyzer (2100 Bioanalyzer, Aligent, Santa Clara,
CA, USA) analysis. The RNA was then diluted to a concentration of 100 ng/µL.
The data discussed in this publication have been deposited in NCBI’s Gene Expression
Omnibus [78] and are accessible through GEO Series accession number GSE87300 (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSExxx).
4.7. Microarray Analysis
The RNA samples were sent to the Ramaciotti Centre, Randwick, Australia for analysis.
An Affymetrix PrimeView™ gene array was used to quantify gene expression, analysed by the
GeneChip Scanner 3000 7G (Affymetrix).
4.8. Quality Control of Arrays
Quality assessment of the microarrays was completed using Affymetrix Expression Console
(Thermo Fisher Scientific) and the BioConductor package “affy” [79] in R, version 3.1.3 [80].
4.9. Differential Gene Expression
To detect changes after OLE intervention, the full set of OLE volunteer arrays were compared
to the paired baseline array. The arrays from the PBO volunteer group were also compared to their
baseline array. Changes in the PBO arm arrays were used to control for the natural fluctuation in gene
expression that would also be expected within the OLE arm. A mathematical linear model was used
to calculate differences between the intervention groups and timepoints. The age variation was also
accounted for in the linear model.
The package “ggplot” in R was used to visualize the expression of specific probe sets or genes of
interest pre and post-supplementation and between treatment groups.
4.10. Gene Ontology
Gene Ontology (GO) analysis was carried out with PANTHER to elucidate biological process,
molecular function and the protein class [17]. The Gene Ontology project is a bioinformatics initiative
encompassing knowledge of how genes encode biological functions at the molecular, cellular and
tissue system levels.
Significantly altered genes were also entered into GATHER [19], which creates a Bayes factor.
This is a measure of the strength of the evidence supporting an association of an annotation with the
gene list submitted [19]. Higher Bayes factors indicate stronger evidence that the annotation is relevant
to the genes of interest [81]. A positive Bayes factor indicates that the evidence supports the hypothesis
that the annotation is more related to the genes of interest than other genes in the genome. This can
create bias when looking for pathway and gene group changes because the strength of the Bayes factor
is based upon the ratio of genes altered from a pathway to the genes altered. GATHER gene expression
analysis is a preliminary analysis specialising in identifying the potential pathways of interest based
on the genes found to be significantly affected.
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4.11. Ingenuity Pathway Analysis (IPA)
Pathway analysis of the differentially expressed genes was performed using IPA software
(2000–2016, QIAGEN, Redwood City, CA, USA). This program constructs gene interactions based
on the regularly updated Ingenuity Knowledge Base (http://www.ingenuity.com). This program
is also able to predict in which direction these changes are likely to impact: inhibitory or activating.
The statistical modelling behind IPA uses the Fisher exact test [82] to determine significant pathways
from the input gene list.
4.12. Gene Expression Validation with Real-Time PCR
To confirm the microarray results, TaqMan real-time PCR analysis was performed for EGR1, ID3
and COX-2 following the manufacturer’s protocol. Two housekeeping genes (GAPDH and β-actin)
were used to control for expression.
4.13. Statistical Analysis of Real-Time PCR
Gene expression levels were calculated with the equation: 2∆∆Ct [83]. The gene expression results
for housekeeping genes were combined allowing for greater accuracy [84]. An absolute FC was
calculated to allow ease of analysis, and this was calculated with the equation: −2ˆLog2(FC). An FC
greater than 1 was classified as an upregulation of gene expression and less than 1 was classified as
downregulation of gene expression. As with the statistical analysis of the microarray data, the PBO
was used to adjust for the FC in OLE participants. In order to calculate the FC differences between
OLE and PBO, data for the participants treated with OLE was adjusted with participants treated with
PBO following calibration, using a modified formula from Section 4.9.
(OLE_T2 calibrated with OLE_T1) − (PBO_T2 calibrated with PBO_T1)
If the range of standard error of the mean intersected with 1 or −1, then the expression was
considered non-significant.
A Students t-test was used to calculate the differences in gene expression between the OLE
treatment and PBO treatment. Two tailed p-values were calculated EGR1 p = 0.025, COX-2 p = 0.016
and ID3 p = 0.023.
5. Conclusions
To conclude, the gene expression profile observed in this study with OLE may explain health
benefits described in previous studies. Improvements in BP [9] and insulin sensitivity [10] measured
in humans after the consumption of OLE relate to regulation of phospholipase metabolic and
inflammatory pathways. Anti-inflammatory gene expression in humans could explain the claimed
health outcomes for cold and influenzas, and chronic anti-inflammatory alterations to gene expression
could explain reduced prevalence of cardiovascular disease and cancers.
Literature supports olive polyphenol ability to improve health outcomes related to inflammation.
What bioactive components of the OLE are interacting with the inflammatory pathways deserves
further analysis. The anti-inflammatory expression induced with OLE could be a result of manipulation
of lipid metabolism or vice versa, but further investigation is required.
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AA Arachidonic acid
AP1 Activator protein 1
COX-2 Prostaglandin-endoperoxide synthase 2 or cyclooxygenase 2
EGR1 Early growth response 1
ERK Extracellular signal-regulated kinase
FC Fold change
FFA Free fatty acid
GO Gene ontology
G0S2 G0/G2 switch gene 2
HBEGF Heparin-binding EGF-like growth factor
HT Hydroxytyrosol
ID3 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein
KO Knock out
MIF Macrophage migration inhibitory factor
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
OLE Olive leaf extract






Phospholipase, phospholipase A2, phospholipase C, secreted phospholipase,
cystolic phospholipase
Appendix A
Table A1. Characteristics of study participants pre- and post-supplementation.
Measurement Olive Leaf Extract Group n Placebo Group n
Age 32 years (mean) 34.5 years (mean)
20–29 9 20–29 7
30–39 3 30–39 2
40–49 1 40–49 2
>50 2 >50 2
Smoking Status
Never 12 Never 9
Former 3 Former 4
Current 0 Current 0
BMI Pre-supplement 24.93 kg/m2 (mean) 24.21 kg/m2 (mean)
<20 0 <20 0
≥20–≤25 10 ≥20–≤25 9
>25–≤30 3 >25–≤30 4
>30 2 >30 1
BMI Post-supplement 24.26 kg/m2 (mean) 24.07 kg/m2 (mean)
<20 0 <20 0
≥20–≤25 10 ≥20–≤25 9
>25–≤30 4 >25–≤30 4
>30 1 >30 1
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Table A2. Ingredients for placebo and OLE supplement.
Placebo-Recipe Olive Leaf Extract
30 L Glycerol 15 L Vegetable glycerol (bulking agent)
15 g Sucrose octa acetate added to 30 L water
15 L Olea europaeo (Olive) Leaf extract
(water, olive leaf solids) equivalent to 15 g
fresh leaf (5 g fresh leaf per 5 mL dose)




Table A3. Phenolic content in Comvita OLE (HPLC performed by Alistair Binney from the Comvita
team. The placebo was also run for quality control and no polyphenols were detected).




Luteolin 7-O-glucoside 0.1 2
Tyrosol 0.07 1.4
Vanillin Acid 0.03 0.6
Apigenin-7-O-glucoside 0.02 0.4





Table A4. Results generated in Gene Annotation Tool to Help Explain Relationships (GATHER) using
the Gene ontology (GO) database.
Gene Ontology at >1.4 FC Number of Genes p-Value Bayes Factor
Regulation of physiological process 13 <0.0001 10
Regulation of biological process 13 <0.0001 8
Development 9 0.0002 5
Regulation of metabolism 9 0.0004 4
Cyclooxygenase pathway 1 0.0008 4
Regulation of transcription,
DNA-dependent 8 0.001 3
Transcription, DNA-dependent 8 0.001 3
Regulation of transcription 8 0.002 3
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